Biomakers raised $8 million from strategic and venture investors, including Labcorp Venture Fund and Oncology Ventures, to scale its AI‑enabled precision oncology platform and expand molecular testing into Latin America. The San Francisco‑based company links a >100,000‑case biobank with high‑throughput genomic testing and clinical‑genomic datasets focused on under‑sampled populations. Management said the financing moves the company from infrastructure building to platform scaling and aims to help drug developers derisk R&D, broaden trial access, and support regulatory relevance for diverse patient groups. The company also appointed Ezequiel Renzulli as chief operating officer to lead commercialization and operations.